SI2694111T1 - Antibody-drug conjugates - Google Patents

Antibody-drug conjugates

Info

Publication number
SI2694111T1
SI2694111T1 SI201230704A SI201230704A SI2694111T1 SI 2694111 T1 SI2694111 T1 SI 2694111T1 SI 201230704 A SI201230704 A SI 201230704A SI 201230704 A SI201230704 A SI 201230704A SI 2694111 T1 SI2694111 T1 SI 2694111T1
Authority
SI
Slovenia
Prior art keywords
antibody
drug conjugates
conjugates
drug
Prior art date
Application number
SI201230704A
Other languages
Slovenian (sl)
Inventor
Hans-Peter Gerber
John Francis Dijoseph
Kiran Manohar Khandke
Kimberly Ann Marquette
Puja Sapra
Lioudmila Gennadievna Tchistiakova
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of SI2694111T1 publication Critical patent/SI2694111T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201230704A 2011-04-01 2012-03-19 Antibody-drug conjugates SI2694111T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161470576P 2011-04-01 2011-04-01
US201261593549P 2012-02-01 2012-02-01
US201261602349P 2012-02-23 2012-02-23
PCT/IB2012/051304 WO2012131527A1 (en) 2011-04-01 2012-03-19 Antibody-drug conjugates
EP12711279.5A EP2694111B1 (en) 2011-04-01 2012-03-19 Antibody-drug conjugates

Publications (1)

Publication Number Publication Date
SI2694111T1 true SI2694111T1 (en) 2016-10-28

Family

ID=45895455

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201230704A SI2694111T1 (en) 2011-04-01 2012-03-19 Antibody-drug conjugates

Country Status (26)

Country Link
US (4) US8309094B2 (en)
EP (2) EP3130356A1 (en)
JP (3) JP5925875B2 (en)
KR (2) KR101529810B1 (en)
CN (2) CN103517719B (en)
AR (1) AR085747A1 (en)
AU (3) AU2012235817B2 (en)
BR (1) BR112013025186A2 (en)
CA (1) CA2830338C (en)
CO (1) CO6771458A2 (en)
DK (1) DK2694111T3 (en)
ES (1) ES2596194T3 (en)
HK (2) HK1193052A1 (en)
HU (1) HUE031017T2 (en)
IL (1) IL228404A0 (en)
MX (1) MX342860B (en)
MY (1) MY170719A (en)
PE (1) PE20140573A1 (en)
PL (1) PL2694111T3 (en)
PT (1) PT2694111T (en)
RU (1) RU2624141C2 (en)
SA (1) SA112330402B1 (en)
SG (2) SG10201605401WA (en)
SI (1) SI2694111T1 (en)
TW (2) TWI549968B (en)
WO (1) WO2012131527A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
IL163852A0 (en) 2002-03-01 2005-12-18 Immunomedics Inc Rs7 antibodies
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP1994055B1 (en) 2006-03-10 2014-07-02 Wyeth LLC Anti-5t4 antibodies and uses thereof
AU2011262346B2 (en) * 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
JP5925875B2 (en) * 2011-04-01 2016-05-25 ワイス・エルエルシー Antibody-drug conjugate
WO2013068874A1 (en) * 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
EP2807485B1 (en) 2012-01-24 2019-03-13 Pfizer Inc Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject
CA2869704A1 (en) * 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
EP2911699B1 (en) * 2012-10-23 2017-11-15 SynAffix B.V. Modified antibody, antibody-conjugate and process for the preparation thereof
TWI589590B (en) * 2012-11-07 2017-07-01 輝瑞股份有限公司 Anti-notch3 antibodies and antibody-drug conjugates
EP2928503B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Conjugates of auristatin compounds
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
KR102356017B1 (en) 2012-12-13 2022-01-27 이뮤노메딕스, 인코오포레이티드 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2014137931A1 (en) * 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
WO2014160305A1 (en) 2013-03-14 2014-10-02 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates and silicon-based linkers
LT2991683T (en) 2013-05-02 2019-12-27 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
RU2015156888A (en) 2013-06-04 2017-07-14 Сайтомкс Терапьютикс, Инк. COMPOSITIONS AND METHODS OF CONJUGATION OF ACTIVATED ANTIBODIES
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015017552A1 (en) 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
HUE046816T2 (en) 2013-10-11 2020-03-30 Asana Biosciences Llc Protein-polymer-drug conjugates
US9849191B2 (en) 2013-10-11 2017-12-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
AU2014342610A1 (en) 2013-11-04 2016-06-02 Abbvie Stemcentrx Llc Anti-EFNA4 antibody-drug conjugates
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
US20150320706A1 (en) 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
JP6517240B2 (en) * 2014-05-22 2019-05-22 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． Site-Specific Conjugation of Linker Drug to Antibody and ADC Obtained
EP3148580B1 (en) 2014-05-29 2021-01-20 MacroGenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
AU2015329625B2 (en) 2014-10-10 2018-04-05 Pfizer Inc. Synergistic auristatin combinations
WO2016133927A1 (en) * 2015-02-16 2016-08-25 New York Blood Center, Inc. Antibody drug conjugates for reducing the latent hiv reservoir
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
CN106279352B (en) * 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 Derivative of dolastatin 10 and application thereof
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN108348608B (en) * 2015-11-24 2022-02-08 拜奥迪斯私人有限公司 anti-5T 4 antibodies and antibody-drug conjugates
CN110698558B (en) * 2015-12-24 2021-09-10 凯惠科技发展(上海)有限公司 TPBG antibody, preparation method thereof, conjugate thereof and application thereof
CA3011372A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US20200338210A1 (en) * 2016-12-22 2020-10-29 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
CN108285487B (en) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 anti-5T 4 antibody-drug conjugate and application thereof
JP7277388B2 (en) 2017-03-15 2023-05-18 オックスフォード バイオメディカ（ユーケー）リミテッド Method
CA3050332A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
CN108690136B (en) * 2017-04-05 2022-09-20 凯惠科技发展(上海)有限公司 Humanized anti-TPBG antibody, preparation method thereof, conjugate thereof and application thereof
EP3624854A1 (en) 2017-05-16 2020-03-25 Université de Strasbourg Protein-drug conjugates and their use in the treatment of cancers
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
TW201929908A (en) 2017-12-21 2019-08-01 美商梅爾莎納醫療公司 Pyrrolobenzodiazepine antibody conjugates
CN110507824A (en) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 A kind of Anti-mesothelin antibodies and its antibody drug conjugate
EA202191175A1 (en) 2018-10-29 2021-09-08 Мерсана Терапьютикс, Инк. CYSTEINE-DESIGNED ANTIBODY-DRUG CONJUGATES CONTAINING PEPTIDE-CONTAINING LINKERS
WO2021048423A1 (en) * 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
AU2021240037A1 (en) 2020-03-20 2022-09-22 Immunomedics, Inc. Biomarkers for sacituzumab govitecan therapy
WO2023045141A1 (en) * 2021-09-26 2023-03-30 上海迈泰君奥生物技术有限公司 Bifunctional fusion protein
WO2023107954A1 (en) * 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023155925A1 (en) * 2022-02-21 2023-08-24 Concept To Medicine Biotech Co., Ltd. Anti-5t4 antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
KR101520209B1 (en) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. Monomethylvaline compounds capable of conjugation to ligands
AR050642A1 (en) * 2004-09-10 2006-11-08 Wyeth Corp ANTI-5T4 HUMANIZED AND CONJUGATED ANTIBODIES ANTI-5T4 ANTIBODY / CALICHEAMICINA
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
WO2007100385A2 (en) 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
WO2007067602A1 (en) * 2005-12-06 2007-06-14 Wyeth Interleukin-11 compositions and methods of use
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP1994055B1 (en) * 2006-03-10 2014-07-02 Wyeth LLC Anti-5t4 antibodies and uses thereof
AR059900A1 (en) * 2006-03-17 2008-05-07 Genentech Inc ANTI-TAT226 ANTIBODIES AND IMMUNOCATE PLAYERS
US8044778B2 (en) * 2007-07-12 2011-10-25 Henry Schein, Inc. Injection device and case with reporting ability
JP5394246B2 (en) * 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド Antibodies and immunoconjugates and methods for their use
PT2211904T (en) * 2007-10-19 2016-11-02 Seattle Genetics Inc Cd19 binding agents and uses thereof
US8521761B2 (en) * 2008-07-18 2013-08-27 Google Inc. Transliteration for query expansion
JP5788863B2 (en) 2009-03-27 2015-10-07 ワイス・エルエルシー Tumor initiating cells and methods of use thereof
JP5925875B2 (en) * 2011-04-01 2016-05-25 ワイス・エルエルシー Antibody-drug conjugate

Also Published As

Publication number Publication date
MX2013011353A (en) 2013-12-16
MX342860B (en) 2016-10-14
PL2694111T3 (en) 2017-01-31
HK1221153A1 (en) 2017-05-26
US20170319711A1 (en) 2017-11-09
KR20150018903A (en) 2015-02-24
AU2017272321A1 (en) 2018-01-04
HUE031017T2 (en) 2017-06-28
IL228404A0 (en) 2013-12-31
EP2694111B1 (en) 2016-08-10
AU2016203839A1 (en) 2016-06-23
EP3130356A1 (en) 2017-02-15
BR112013025186A2 (en) 2018-09-11
SG193324A1 (en) 2013-10-30
KR101783529B1 (en) 2017-09-29
CN105288644A (en) 2016-02-03
MY170719A (en) 2019-08-27
PE20140573A1 (en) 2014-05-14
AU2012235817A1 (en) 2013-10-10
US20140081005A1 (en) 2014-03-20
CN103517719B (en) 2016-10-12
ES2596194T3 (en) 2017-01-05
KR101529810B1 (en) 2015-06-26
RU2013142004A (en) 2015-05-10
NZ615308A (en) 2015-10-30
SG10201605401WA (en) 2016-08-30
EP2694111A1 (en) 2014-02-12
AR085747A1 (en) 2013-10-23
SA112330402B1 (en) 2015-03-18
US8586049B2 (en) 2013-11-19
AU2012235817B2 (en) 2016-03-10
JP2016172747A (en) 2016-09-29
DK2694111T3 (en) 2016-10-10
WO2012131527A1 (en) 2012-10-04
PT2694111T (en) 2016-10-20
US20130011418A1 (en) 2013-01-10
KR20130125833A (en) 2013-11-19
TWI471334B (en) 2015-02-01
JP2018140997A (en) 2018-09-13
HK1193052A1 (en) 2014-09-12
US20120251558A1 (en) 2012-10-04
TW201302795A (en) 2013-01-16
CN103517719A (en) 2014-01-15
TWI549968B (en) 2016-09-21
TW201534624A (en) 2015-09-16
CO6771458A2 (en) 2013-10-15
RU2624141C2 (en) 2017-06-30
JP5925875B2 (en) 2016-05-25
JP2014516508A (en) 2014-07-17
JP6333882B2 (en) 2018-05-30
CA2830338A1 (en) 2012-10-04
CA2830338C (en) 2016-11-15
US8309094B2 (en) 2012-11-13

Similar Documents

Publication Publication Date Title
IL263973B (en) Protein-polymer-drug conjugates
HUS2300020I1 (en) Pyrrolobenzodiazepine-antibody conjugates
ZA201900820B (en) Antibody-drug conjugate
SG10201605401WA (en) Antibody-drug conjugates
HK1196257A1 (en) P97-antibody conjugates p97-
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
IL232936A0 (en) Antibody-drug conjugates and related compounds, compositions, and methods
EP2797959A4 (en) Aspartyl-trna synthetase-fc conjugates
EP2776070A4 (en) Immunomodulatory conjugates